Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform

Inspire Biotherapeutics Inc., an emerging biotech company with a mission to create life-saving gene therapies for monogenic and acquired diseases of the lung, is poised to move its novel lung tropic AAV gene therapy into clinical validation.

The AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. The platform can be applied to treat cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and other monogenic lung diseases.

Inspire’s scientific founders – Dr. Bernard Thébaud, chief medical officer, – a neonatologist and cell therapy pioneer in neonates - and Dr. Sarah Wootton, chief scientific officer, – a vectorologist with extensive AAV experience – say they are pursuing initiation of a first-in-human clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy.

The company launch is supported by three business founders – C3i Center Inc., Octane Medical Group of Companies, and the Ontario Institute for Regenerative Medicine – with deep expertise in company creation, translational teams, and regenerative medicine commercialization.

Inspire Biotherapeutics presented at the OBIO® Investment Summit.